Trial Profile
A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab Combined With Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 08 Aug 2021 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 08 Aug 2021 Status changed from completed to active, no longer recruiting.
- 08 Jun 2021 Status changed from not yet recruiting to completed, as per results presented at the 57th Annual Meeting of the American Society of Clinical Oncology.